The AML also lost mutations in cancer genes toward the end of treatment in comparison with initiation, e.g., in IL3 (p.P27S, VAF 9.3%) and NCOR2 (p.G1830delinsSSGG, VAF 19.6%). This evidence concerns the gene NCOR2 and acute myeloid leukemia.